Analytical Data
-
Gene name
BD-1
- Application
-
Alternative Names
rHuBD-1; HBD1; DEFB1
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P60022
-
Expression Region
G22-K68
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
5.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BD-1, a member of the defensin family of antimicrobial peptides, plays a crucial role in the innate immune system by exhibiting antimicrobial and immunomodulatory properties. Its discovery has sparked significant interest in understanding its mechanisms of action and potential therapeutic applications. Research indicates that BD-1 not only enhances the host's defense against various pathogens, including bacteria and viruses, but also modulates the immune response by influencing cytokine production and cell signaling pathways. The recombinant form of BD-1, produced through recombinant DNA technology, allows for detailed studies on its structure-function relationships and facilitates the exploration of its potential as a novel antimicrobial agent. Recent studies have focused on optimizing its expression and purification methods to ensure high yield and bioactivity. Furthermore, the exploration of BD-1's efficacy in various disease models, including respiratory infections and skin disorders, suggests its promise as a therapeutic candidate. The continued investigation into BD-1's biological functions and its interactions with other components of the immune system may pave the way for innovative treatment strategies, particularly in an era marked by increasing antibiotic resistance. Establishing BD-1 as a viable therapeutic agent could not only enhance our understanding of innate immunity but also contribute significantly to the development of new approaches in combating infectious diseases.











